Annual EBITDA
-$1.83 M
-$1.80 M-5071.47%
December 31, 2023
Summary
- As of March 3, 2025, BLACU annual EBITDA is -$1.83 million, with the most recent change of -$1.80 million (-5071.47%) on December 31, 2023.
- During the last 3 years, BLACU annual EBITDA has fallen by -$7.33 million (-133.27%).
- BLACU annual EBITDA is now -133.27% below its all-time high of $5.50 million, reached on December 1, 2020.
Performance
BLACU EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$454.10 K
+$21.40 K+4.50%
September 30, 2024
Summary
- As of March 3, 2025, BLACU quarterly EBITDA is -$454.10 thousand, with the most recent change of +$21.40 thousand (+4.50%) on September 30, 2024.
- Over the past year, BLACU quarterly EBITDA has dropped by -$3300.00 (-0.73%).
- BLACU quarterly EBITDA is now -454000.00% below its all-time high of -$100.00, reached on September 1, 2021.
Performance
BLACU Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$2.24 M
-$43.70 K-1.99%
September 30, 2024
Summary
- As of March 3, 2025, BLACU TTM EBITDA is -$2.24 million, with the most recent change of -$43.70 thousand (-1.99%) on September 30, 2024.
- Over the past year, BLACU TTM EBITDA has dropped by -$238.90 thousand (-11.92%).
- BLACU TTM EBITDA is now -149386.67% below its all-time high of -$1500.00, reached on June 1, 2022.
Performance
BLACU TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
BLACU EBITDA Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -5071.5% | -0.7% | -11.9% |
3 y3 years | -133.3% | -0.7% | -11.9% |
5 y5 years | +65.9% | -0.7% | -11.9% |
BLACU EBITDA Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | <-9999.0% | at low | <-9999.0% | +47.3% | <-9999.0% | at low |
5 y | 5-year | -133.3% | at low | <-9999.0% | +47.3% | <-9999.0% | at low |
alltime | all time | -133.3% | +90.9% | <-9999.0% | +47.3% | <-9999.0% | at low |
Bellevue Life Sciences Acquisition EBITDA History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | -$454.10 K(-4.5%) | -$2.24 M(+2.0%) |
Jun 2024 | - | -$475.50 K(+5.5%) | -$2.20 M(+9.7%) |
Mar 2024 | - | -$450.80 K(-47.7%) | -$2.00 M(+9.4%) |
Dec 2023 | -$1.83 M(+5071.5%) | -$861.90 K(+110.0%) | -$1.83 M(+86.2%) |
Sep 2023 | - | -$410.40 K(+46.4%) | -$983.10 K(+65.9%) |
Jun 2023 | - | -$280.30 K(+0.8%) | -$592.70 K(+89.1%) |
Mar 2023 | - | -$278.10 K(+1844.8%) | -$313.40 K(+785.3%) |
Dec 2022 | -$35.40 K | - | - |
Dec 2022 | - | -$14.30 K(-28.5%) | -$35.40 K(+65.4%) |
Sep 2022 | - | -$20.00 K(+1900.0%) | -$21.40 K(+1326.7%) |
Jun 2022 | - | -$1000.00(+900.0%) | -$1500.00(-53.1%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2022 | - | -$100.00(-66.7%) | -$3200.00(+3.2%) |
Dec 2021 | -$3300.00(-100.1%) | -$300.00(+200.0%) | -$3100.00(+10.7%) |
Sep 2021 | - | -$100.00(-96.3%) | -$2800.00(+3.7%) |
Jun 2021 | - | -$2700.00 | -$2700.00 |
Dec 2020 | $5.50 M(-1207.2%) | - | - |
Dec 2019 | -$497.00 K(-90.7%) | - | - |
Dec 2018 | -$5.36 M(-69.4%) | - | - |
Dec 2017 | -$17.51 M(+6.1%) | - | - |
Dec 2016 | -$16.51 M(-17.8%) | - | - |
Dec 2015 | -$20.07 M(+324.9%) | - | - |
Dec 2014 | -$4.72 M | - | - |
FAQ
- What is Bellevue Life Sciences Acquisition annual EBITDA?
- What is the all time high annual EBITDA for Bellevue Life Sciences Acquisition?
- What is Bellevue Life Sciences Acquisition annual EBITDA year-on-year change?
- What is Bellevue Life Sciences Acquisition quarterly EBITDA?
- What is the all time high quarterly EBITDA for Bellevue Life Sciences Acquisition?
- What is Bellevue Life Sciences Acquisition quarterly EBITDA year-on-year change?
- What is Bellevue Life Sciences Acquisition TTM EBITDA?
- What is the all time high TTM EBITDA for Bellevue Life Sciences Acquisition?
- What is Bellevue Life Sciences Acquisition TTM EBITDA year-on-year change?
What is Bellevue Life Sciences Acquisition annual EBITDA?
The current annual EBITDA of BLACU is -$1.83 M
What is the all time high annual EBITDA for Bellevue Life Sciences Acquisition?
Bellevue Life Sciences Acquisition all-time high annual EBITDA is $5.50 M
What is Bellevue Life Sciences Acquisition annual EBITDA year-on-year change?
Over the past year, BLACU annual EBITDA has changed by -$1.80 M (-5071.47%)
What is Bellevue Life Sciences Acquisition quarterly EBITDA?
The current quarterly EBITDA of BLACU is -$454.10 K
What is the all time high quarterly EBITDA for Bellevue Life Sciences Acquisition?
Bellevue Life Sciences Acquisition all-time high quarterly EBITDA is -$100.00
What is Bellevue Life Sciences Acquisition quarterly EBITDA year-on-year change?
Over the past year, BLACU quarterly EBITDA has changed by -$3300.00 (-0.73%)
What is Bellevue Life Sciences Acquisition TTM EBITDA?
The current TTM EBITDA of BLACU is -$2.24 M
What is the all time high TTM EBITDA for Bellevue Life Sciences Acquisition?
Bellevue Life Sciences Acquisition all-time high TTM EBITDA is -$1500.00
What is Bellevue Life Sciences Acquisition TTM EBITDA year-on-year change?
Over the past year, BLACU TTM EBITDA has changed by -$238.90 K (-11.92%)